The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
Mitoxantrone, More than Just Another Topoisomerase II Poison
Abstract
Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. A comprehensive overview of the drug's molecular, biochemical, and cellular pharmacology is presented here, beginning with the cardiotoxic nature of its predecessor doxorubicin and how these properties shaped the pharmacology of mitoxantrone itself. Although mitoxantrone is firmly established as a DNA topoisomerase II poison within mammalian cells, it is now clear that the drug interacts with a much broader range of biological macromolecules both covalently and noncovalently. Here, we consider each of these interactions in the context of their wider biological relevance to cancer therapy and highlight how they may be exploited to further enhance the therapeutic value of mitoxantrone. In doing so, it is now clear that mitoxantrone is more than just another topoisomerase II poison.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Etienne-Manneville, S., & Hall, A. (2002) · Nature · doi:10.1038/nature01148 · Cited by 4,201
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Myeloperoxidase: friend and foe
Klebanoff, S. J. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1204697 · Cited by 2,282
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Activation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580
The power and the promise of DNA methylation markers
Laird, P. W. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1045 · Cited by 1,562
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Cancer—Principles & Practice of Oncology
Rhoads, J. E. (1983) · PubMed Central · Cited by 1,466
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc749 · Cited by 1,349
A distinct “side population” of cells with high drug efflux capacity in human tumor cells
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A., & Brenner, M. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400067101 · Cited by 1,280
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., & Qin, J. (2000) · Genes & Development · doi:10.1101/gad.14.8.927 · Cited by 1,221
DNA methylation in health and disease
Robertson, K. D., & Wolffe, A. P. (2000) · Nature Reviews Genetics · doi:10.1038/35049533 · Cited by 1,057
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
Rhee, I., Bachman, K. E., Park, B. H., Jair, K.-W., Yen, R.-W. C., Schuebel, K. E., Cui, H., Feinberg, A. P., Lengauer, C., Kinzler, K. W., et al. (2002) · Nature · doi:10.1038/416552a · Cited by 1,039
Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 890
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Miyake, K., Mickley, L. A., Litman, T., Zhan, Z., Robey, R. W., Cristensen, B., Brangi, M., Greenberger, L., Dean, M. C., Fojo, T., et al. (1999) · PubMed · Cited by 823
Bleau, A.-M., Hambardzumyan, D., Ozawa, T., Fomchenko, E. I., Huse, J. T., Brennan, C. W., & Holland, E. C. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.01.007 · Cited by 808
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., & Friend, S. H. (1997) · Science · doi:10.1126/science.278.5340.1064 · Cited by 773
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., & Deeley, R. G. (1994) · PubMed · Cited by 770
The MRE11 complex: starting from the ends
Stracker, T. H., & Petrini, J. H. J. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3047 · Cited by 734
Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., & Green, D. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80054-4 · Cited by 721
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., Margolick, J. B., Liotta, L. A., Petricoin, E., & Zhang, Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702596104 · Cited by 698
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
A general mechanism for microsomal activation of quinone anticancer agents to free radicals.
Bachur, N. R., Gordon, S. L., & Gee, M. V. (1978) · PubMed · Cited by 639
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow, J. H. (1983) · PubMed · Cited by 629
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
The anthracyclines: will we ever find a better doxorubicin?
Weiss, R. B. (1992) · PubMed · Cited by 558
Cancer biology and NuRD: a multifaceted chromatin remodelling complex
Lai, A. Y., & Wade, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3091 · Cited by 539
Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
Wu, C.-C., Li, T.-K., Farh, L., Lin, L.-Y., Lin, T.-S., Yu, Y.-J., Yen, T.-J., Chiang, C.-W., & Chan, N.-L. (2011) · Science · doi:10.1126/science.1204117 · Cited by 523
Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism
Froelich-Ammon, S. J., & Osheroff, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21429 · Cited by 505
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
Burden, D. A., & Osheroff, N. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00132-8 · Cited by 503
NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals.
Bachur, N. R., Gordon, S. L., Gee, M. V., & Kon, H. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.2.954 · Cited by 489
Dumaz, N., & Meek, D. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.24.7002 · Cited by 455
Sharp, P. A. (2009) · Cell · doi:10.1016/j.cell.2009.02.007 · Cited by 455
Gorczyca, W., Gong, J., Ardelt, B. K., Traganos, F., & Darżynkiewicz, Z. (1993) · PubMed · Cited by 388
Momparler, R. L., & Bovenzi, V. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200005)183:2<145::aid-jcp1>3.0.co;2-v · Cited by 387
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Ewer, M. S., & Ewer, S. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.121 · Cited by 373
Targeting cancer cells: magnetic nanoparticles as drug carriers
Alexiou, C., Schmid, R. J., Jurgons, R., Kremer, M., Wanner, G., Bergemann, C., Huenges, E., Nawroth, T., Arnold, W., & Parak, F. G. (2006) · European Biophysics Journal · doi:10.1007/s00249-006-0042-1 · Cited by 362
Ross, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P. C., & Doyle, L. A. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.429 · Cited by 350
Hollingshead, L. M., & Faulds, D. (1991) · Drugs · doi:10.2165/00003495-199142040-00010 · Cited by 345
DNA repair deficiency and neurological disease
McKinnon, P. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2559 · Cited by 323
Zingg, J. (1997) · Carcinogenesis · doi:10.1093/carcin/18.5.869 · Cited by 321
Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II–Mediated Form of Cell Death
Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R., & Cutts, S. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3410 · Cited by 314
Self-citationEvidence of a specific complex between adriamycin and negatively-charged phospholipids
Goormaghtigh, E., Chatelain, P., Caspers, J., & Ruysschaert, J. M. (1980) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(80)90145-5 · Cited by 310
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
SHENKENBERG, T. D., & VON HOFF, D. D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-67 · Cited by 305
Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble
Stelzer, A. C., Frank, A. T., Kratz, J. D., Swanson, M. D., Gonzalez-Hernandez, M. J., Lee, J., Andricioaei, I., Markovitz, D. M., & Al-Hashimi, H. M. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.596 · Cited by 291
(2003) · PubMed · Cited by 290
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
Mistry, A. R., Felix, C. A., Whitmarsh, R. J., Mason, A., Reiter, A., Cassinat, B., Parry, A., Walz, C., Wiemels, J. L., Segal, M. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042715 · Cited by 281
Recent Advances in Developing Small Molecules Targeting RNA
Guan, L., & Disney, M. D. (2012) · ACS Chemical Biology · doi:10.1021/cb200447r · Cited by 280
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).
Bonadonna, G., Monfardini, S., Lena, M. D., Fossati‐Bellani, F., & Beretta, G. (1970) · PubMed · Cited by 278
Islam, S. A., Neidle, S., Gandecha, B. M., Partridge, M., Patterson, L. H., & Brown, J. R. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00145a003 · Cited by 276
Berlin, V., & Haseltine, W. A. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69315-4 · Cited by 275
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 262
Capranico, G., Tinelli, S., Austin, C. A., Fisher, M. L., & Zunino, F. (1992) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(92)90050-a · Cited by 258
The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey
Madden, T. D., Harrigan, P. R., Tai, L. C. L., Bally, M. B., Mayer, L. D., Redelmeier, T. E., Loughrey, H. C., Tilcock, C. P. S., Reinish, L. W., & Cullis, P. R. (1990) · Chemistry and Physics of Lipids · doi:10.1016/0009-3084(90)90131-a · Cited by 255
Adriamycin stimulated superoxide formation in submitochondrial particles
Thayer, W. S. (1977) · Chemico-Biological Interactions · doi:10.1016/0009-2797(77)90050-3 · Cited by 251
Kasibhatla, S., Genestier, L., & Green, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.987 · Cited by 250
‘Daunomycin’, a New Antibiotic of the Rhodomycin Group
DI MARCO, A., GAETANI, M., OREZZI, P., SCARPINATO, B. M., SILVESTRINI, R., SOLDATI, M., DASDIA, T., & VALENTINI, L. (1964) · Nature · doi:10.1038/201706a0 · Cited by 250
Henderson, I. C., Allegra, J. C., Woodcock, T. M., Wolff, S., Bryan, S., Cartwright, K. J., Dukart, G., & Henry, D. W. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.560 · Cited by 246
Schneider, E., Horton, J. K., Yang, J. C., Nakagawa, M., & Cowan, K. H. (1994) · PubMed · Cited by 244
Foster, R., Hu, K.-Q., Lu, Y., Nolan, K. M., Thissen, J., & Settleman, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.6.2689 · Cited by 240
Qualitative and quantitative aspects of intercalator-induced DNA strand breaks
Ross, W. E., Glaubiger, D., & Kohn, K. W. (1979) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(79)90124-2 · Cited by 237
Protein-associated DNA breaks in cells treated with adriamycin or ellipticine
Ross, W. E., Glaubiger, D. L., & Kohn, K. W. (1978) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(78)90059-x · Cited by 236
Faulds, D., Balfour, J. A., Chrisp, P., & Langtry, H. D. (1991) · Drugs · doi:10.2165/00003495-199141030-00007 · Cited by 236
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Xu, X., Persson, H. L., & Richardson, D. R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013383 · Cited by 235
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review
Aubel-Sadron, G., & Londos-Gagliardi, D. (1984) · Biochimie · doi:10.1016/0300-9084(84)90018-x · Cited by 233
Vejpongsa, P., & Yeh, E. T. H. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.201 · Cited by 225
Clinical Evaluation of Adriamycin, a New Antitumour Antibiotic
Bonadonna, G., Monfardini, S., de Lena, M., & Fossati-Bellani, F. (1969) · BMJ · doi:10.1136/bmj.3.5669.503 · Cited by 220
Hypermethylation of tumor suppressor genes in cancer
Herman, J. G. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0138 · Cited by 218
Unraveling the mechanism of BRCA2 in homologous recombination
Holloman, W. K. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2096 · Cited by 215
Therapy-Related Acute Promyelocytic Leukemia
Beaumont, M., Sanz, M., Carli, P. M., Maloisel, F., Thomas, X., Detourmignies, L., Guerci, A., Gratecos, N., Rayon, C., San Miguel, J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.072 · Cited by 215
Double-Strand Break Repair Deficiency and Radiation Sensitivity in BRCA2 Mutant Cancer Cells
Abbott, D. W., Holt, J. T., & Freeman, M. L. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.13.978 · Cited by 206
Huang, X., Okafuji, M., Traganos, F., Luther, E., Holden, E., & Darzynkiewicz, Z. (2004) · Cytometry Part A · doi:10.1002/cyto.a.20018 · Cited by 197
On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
Wu, C.-C., Li, Y.-C., Wang, Y.-R., Li, T.-K., & Chan, N.-L. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt828 · Cited by 192
DNA topoisomerases as targets for cancer therapy
Ross, W. E. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90273-4 · Cited by 190
Vaults: a ribonucleoprotein particle involved in drug resistance?
Mossink, M. H., van Zon, A., Scheper, R. J., Sonneveld, P., & Wiemer, E. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206947 · Cited by 187
Simon, J. A., Szankasi, P., Nguyen, D. K., Ludlow, C. L., Dunstan, H. M., Roberts, C. J., Jensen, E. L., Hartwell, L. H., & Friend, S. H. (2000) · PubMed · Cited by 183
Encyclopedia of molecular biology
(1999) · Choice Reviews Online · doi:10.5860/choice.37-1280 · Cited by 177
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., Gödtel-Armbrust, U., & Wojnowski, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-842 · Cited by 176
Minotti, G., Recalcati, S., Mordente, A., Liberi, G., Calafiore, A. M., Mancuso, C., Preziosi, P., & Cairo, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.7.541 · Cited by 173
DNA double-strand breaks in mammalian cells after exposure to intercalating agents
Ross, W. E., & Bradley, M. O. (1981) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(81)90145-3 · Cited by 160
Kato, S., Burke, P., Koch, T. H., & Bierbaum, V. M. (2001) · Analytical Chemistry · doi:10.1021/ac001498q · Cited by 157
Selection for Drug Resistance Results in Resistance to Fas-Mediated Apoptosis
Landowski, T. H., Gleason-Guzman, M. C., & Dalton, W. S. (1997) · Blood · doi:10.1182/blood.v89.6.1854 · Cited by 154
Harker, W. G., Slade, D., Drake, F. H., & Parr, R. L. (1991) · Biochemistry · doi:10.1021/bi00105a020 · Cited by 152
Burden, D. A., Kingma, P. S., Froelich-Ammon, S. J., Bjornsti, M., Patchan, M. W., Thompson, R. B., & Osheroff, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.29238 · Cited by 149
Goormaghtigh, E., Brasseur, R., & Ruysschaert, J. (1982) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(82)91976-3 · Cited by 149
Dietel, M., Arps, H., Lage, H., & Niendorf, A. (1990) · PubMed · Cited by 149
A Protease Pathway for the Repair of Topoisomerase II-DNA Covalent Complexes
Zhang, A., Lyu, Y. L., Lin, C., Zhou, N., Azarova, A. M., Wood, L. M., & Liu, L. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604149200 · Cited by 146
The challenge of breath analysis for clinical diagnosis and therapeutic monitoring
Smith, D. C., & Španěl, P. (2007) · The Analyst · doi:10.1039/b700542n · Cited by 145
NF-κB activation by double-strand breaks
Habraken, Y., & Piette, J. G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.07.015 · Cited by 144
Jones, R. G., Elford, A. R., Parsons, M. J., Wu, L., Krawczyk, C. M., Yeh, W., Hakem, R., Rottapel, R. K., Woodgett, J. R., & Ohashi, P. S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020307 · Cited by 142
Harker, W. G., Slade, D., Dalton, W. S., Meltzer, P. S., & Trent, J. M. (1989) · PubMed · Cited by 140
Nakagawa, M., Schneider, E., Dixon, K. H., Horton, J., Kelley, K., Morrow, C., & Cowan, K. H. (1992) · PubMed · Cited by 136
Huang, X., Traganos, F., & Darżynkiewicz, Z. (2003) · Cell Cycle · doi:10.4161/cc.2.6.565 · Cited by 135
Davies, K. J. A., Doroshow, J. H., & Hochstein, P. E. (1983) · FEBS Letters · doi:10.1016/0014-5793(83)80153-7 · Cited by 132
Ebeler, S. E., Clifford, A. J., & Shibamoto, T. (1997) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00369-1 · Cited by 132
Ambrosone, C. B., Ahn, J., Singh, K. K., Rezaishiraz, H., Furberg, H. F., Sweeney, C., Coles, B., & Trovato, A. (2005) · Cancer Research · doi:10.1158/0008-5472.1105.65.3 · Cited by 132
Yuan, X.-J., & Whang, Y. E. (2002) · Oncogene · doi:10.1038/sj/onc/1205054 · Cited by 132
Molecular and biochemical pharmacology of mitoxantrone
Durr, F. E., Wallace, R. E., & Citarella, R. V. (1983) · Cancer Treatment Reviews · doi:10.1016/0305-7372(83)90016-6 · Cited by 131
Taatjes, D. J., Gaudiano, G., Resing, K. A., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960835d · Cited by 131
The mammalian XRCC genes: their roles in DNA repair and genetic stability
Thacker, J., & Zdzienicka, M. Z. (2003) · DNA repair · doi:10.1016/s1568-7864(03)00062-4 · Cited by 128
Tong, Z., Luo, W., Wang, Y.-Q., Yang, F., Han, Y., Li, H., Luo, H., Duan, B., Xu, T., Mao‐Ying, Q., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010234 · Cited by 124
Adlakha-Hutcheon, G., Bally, M. B., Shew, C. R., & Madden, T. D. (1999) · Nature Biotechnology · doi:10.1038/11710 · Cited by 121
Gao, R., Schellenberg, M. J., Huang, S.-Y. N., Abdelmalak, M., Marchand, C., Nitiss, K. C., Nitiss, J. L., Williams, R. S., & Pommier, Y. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.565374 · Cited by 120
Lu, B., Xiong, S.-B., Yang, H., et al. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.001 · Cited by 120
Resistance to topoisomerase poisons due to loss of DNA mismatch repair
Fedier, A., Schwarz, V. A., Walt, H., Carpini, R. D., Haller, U., & Fink, D. A. (2001) · International Journal of Cancer · doi:10.1002/ijc.1356 · Cited by 117
DNA sequence selectivity of topoisomerases and topoisomerase poisons
Capranico, G., & Binaschi, M. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00135-3 · Cited by 116
Formaldehyde crosslinks daunorubicin and DNA efficiently: HPLC and x-ray diffraction studies
Wang, A. H. ‐., Gao, Y., Liaw, Y. C., & Li, Y. K. (1991) · Biochemistry · doi:10.1021/bi00230a002 · Cited by 115
Identification and Characterization of Inhibitors of Human Apurinic/apyrimidinic Endonuclease APE1
Simeonov, A. M., Kulkarni, A., Dorjsuren, D. G., Jadhav, A., Shen, M., McNeill, D. R., Austin, C. P., & Wilson, D. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005740 · Cited by 112
Pharmacokinetics and Metabolism of Mitoxantrone
Ehninger, G., Schuler, U. S., Proksch, B., Zeller, K., & Blanz, J. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018050-00003 · Cited by 112
Novel Extracellular Vesicles Mediate an ABCG2-Dependent Anticancer Drug Sequestration and Resistance
Ifergan, I., Scheffer, G. L., & Assaraf, Y. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2021 · Cited by 110
Bennett, J. M., Muss, H. B., Doroshow, J. H., Wolff, S., Krementz, E. T., Cartwright, K. J., Dukart, G., Reisman, A., & Schoch, I. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1611 · Cited by 109
Toxicity of the topoisomerase II inhibitors
Seiter, K. P. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.2.219 · Cited by 107
Morrow, C. S., Peklak-Scott, C., Bishwokarma, B., Kute, T. E., Smitherman, P. K., & Townsend, A. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.017988 · Cited by 105
Sazuka, Y., Tanizawa, H., & Takino, Y. (1989) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1989.tb02250.x · Cited by 102
NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform
Toyoda, E., Kagaya, S., Cowell, I. G., Kurosawa, A., Kamoshita, K., Nishikawa, K., Iiizumi, S., Koyama, H., Austin, C. A., & Adachi, N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803936200 · Cited by 102
Nanodiamond–Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells
Toh, T. B., Lee, D.-K., Hou, W., Abdullah, L. N., Nguyen, J., Ho, D., & Chow, E. K. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5001108 · Cited by 99
Zheng, S., Chen, Y., Donahue, C. P., Wolfe, M. S., & Varani, G. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.03.009 · Cited by 99
Lee, C. M., & Tannock, I. F. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603010 · Cited by 98
Schurr, E., Raymond, M., Bell, J. C., et al. (1989) · PubMed · Cited by 97
Seitz, S., Schleithoff, E. S., Koch, A., Schuster, A., Teufel, A., Staib, F., Stremmel, W., Melino, G., Krammer, P. H., Schilling, T., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24861 · Cited by 96
Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism
Regev, R., Yeheskely‐Hayon, D., Katzir, H., & Eytan, G. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.032 · Cited by 95
Harker, W. G., Slade, D., Parr, R., et al. (1995) · PubMed · Cited by 95
Derivatives of butyric acid as potential anti‐neoplastic agents
Rephaeli, A., Rabizadeh, E., Aviram, A., Shaklai, M., Ruse, M., & Nudelman, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490113 · Cited by 86
Mortensen, U. H., Lisby, M., & Rothstein, R. J. (2009) · Current Biology · doi:10.1016/j.cub.2009.06.001 · Cited by 86
Mitoxantrone affects topoisomerase activities in human breast cancer cells
Crespi, M. D., Ivanier, S. E., Genovese, J. A., & Baldi, A. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90471-7 · Cited by 85
Alkylation of DNA by the Anthracycline, Antitumor Drugs Adriamycin and Daunomycin
Taatjes, D. J., Gaudiano, G., Resing, K. A., & Koch, T. H. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960519z · Cited by 84
Influence of Drug Release Characteristics on the Therapeutic Activity of Liposomal Mitoxantrone
Lim, H. J., Masin, D., Madden, T. D., & Bally, M. B. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36596-6 · Cited by 83
A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons
Capranico, G., Binaschi, M., Borgnetto, M. E., Zunino, F., & Palumbo, M. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01095-x · Cited by 82
Disposition of mitoxantrone in cancer patients.
Alberts, D. S., Peng, Y. M., Leigh, S. A., Davis, T. P., & Woodward, D. L. (1985) · PubMed · Cited by 82
The prima donna of epigenetics: the regulation of gene expression by DNA methylation
Santos, K. F., Mazzola, T. N., & Carvalho, H. F. (2005) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2005001000010 · Cited by 81
Cheneval, D., Müller, M., Toni, R., Ruetz, S., & Carafoli, E. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38828-2 · Cited by 75
Tammaro, M., Barr, P., Ricci, B., & Yan, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079202 · Cited by 75
Kurose, A., Tanaka, T., Huang, X., Halicka, H. D., Traganos, F., Dai, W. H., & Darżynkiewicz, Z. (2005) · Cytometry Part A · doi:10.1002/cyto.a.20186 · Cited by 75
Topoisomerase II Is Required for Mitoxantrone to Signal Nuclear Factor κB Activation in HL60 Cells
Boland, M. P., Fitzgerald, K. A., & O'Neill, L. A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.33.25231 · Cited by 74
Busà, R., Geremia, R., & Sette, C. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq004 · Cited by 71
Smith, P. J., Morgan, S. A., Fox, M. E., & Watson, J. V. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90237-f · Cited by 71
Berberine suppresses gero-conversion from cell cycle arrest to senescence
Zhao, H., Halicka, H. D., Li, J., & Darżynkiewicz, Z. (2013) · Aging · doi:10.18632/aging.100593 · Cited by 71
MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA
Lee, K. C., Padget, K., Curtis, H., Cowell, I. G., Moiani, D., Sońdka, Z., Morris, N. J., Jackson, G. H., Cockell, S., Tainer, J. A., et al. (2012) · Biology Open · doi:10.1242/bio.20121834 · Cited by 70
NF-κB-dependent Fas ligand expression
Hsu, S., Gavrilin, M. A., Lee, H., Wu, C., Han, S. H., & Lai, M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199909)29:09<2948::aid-immu2948>3.0.co;2-0 · Cited by 70
Human vault-associated non-coding RNAs bind to mitoxantrone, a chemotherapeutic compound
Gopinath, S. C. B., Matsugami, A., Katahira, M., & Kumar, P. K. R. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki809 · Cited by 69
A Novel High Throughput Biochemical Assay to Evaluate the HuR Protein-RNA Complex Formation
D’Agostino, V., Adami, V., & Provenzani, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072426 · Cited by 68
Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Liu, Q. Y., Rubin, M. A., Omene, C. O., Lederman, S. M., & Stein, C. (1998) · PubMed · Cited by 68
Zhao, H. L., Traganos, F., & Darżynkiewicz, Z. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6750 · Cited by 67
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia
Reiter, A., Sauβele, S., Grimwade, D. J., Wiemels, J. L., Segal, M. R., Lafage‐Pochitaloff, M., Walz, C., Weisser, A., Hochhaus, A., Willer, A., et al. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10154 · Cited by 63
Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses
Fan, J.-R., Peng, A., Chen, H.-C., Lo, S.-C., Huang, T. H., & Li, T. (2008) · DNA repair · doi:10.1016/j.dnarep.2007.12.002 · Cited by 61
Gopinath, S. C. B., Wadhwa, R., & Kumar, P. K. R. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0242 · Cited by 61
Increase therapy-related leukemia secondary to breast cancer
Pm, C., Sgro, C., Parchin-Geneste, N., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401787 · Cited by 61
Lim, H. J., Masin, D., McIntosh, N. L., Madden, T. D., & Bally, M. B. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35297-8 · Cited by 60
Capranico, G., Isabella, P. D., Tinelli, S., Bigioni, M., & Zunino, F. (1993) · Biochemistry · doi:10.1021/bi00063a015 · Cited by 59
Wan, X., Zhang, W., Li, L., Xie, Y., Li, W., & Huang, N. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400045y · Cited by 59
Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells
Hövelmann, S., Beckers, T. L., & Schmidt, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601876 · Cited by 58
Vibet, S., Mahéo, K., Goré, J., Dubois, P., Bougnoux, P., & Chourpa, I. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013474 · Cited by 57
Smith, P., Sykes, H., Fox, M. E., & Furlong, I. J. (1992) · PubMed · Cited by 56
Huang, F.-F., Wu, D., Zhang, L., Yu, Y., Yuan, X., Li, W., Chen, X., Zhao, X., Chen, F., & Zeng, H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.006 · Cited by 55
Targeting DNA repair in breast cancer: A clinical and translational update
Amir, E., Šeruga, B., Serrano, R., & Ocaña, A. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.006 · Cited by 53
Harker, W. G., Slade, D., Parr, R., & Holguin, M. H. (1995) · PubMed · Cited by 52
Duthie, S. J., & Grant, M. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.314 · Cited by 51
Mitoxantrone Analogues as Ligands for a Stem−Loop Structure of Tau Pre-mRNA
Liu, Y., Peacey, E., Dickson, J. R., Donahue, C. P., Zheng, S., Varani, G., & Wolfe, M. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9013407 · Cited by 51
Mitoxantrone: A Review of its Pharmacological Properties and Use in Acute Nonlymphoblastic Leukaemia
Dunn, C. J., & Goa, K. L. (1996) · Drugs & Aging · doi:10.2165/00002512-199609020-00007 · Cited by 48
New biomarkers probing depth of cell senescence assessed by laser scanning cytometry
Zhao, H. L., Halicka, H. D., Traganos, F., Jorgensen, E. D., & Darżynkiewicz, Z. (2010) · Cytometry Part A · doi:10.1002/cyto.a.20983 · Cited by 47
Mantovani, G., Macciò, A., Pisano, M., Versace, R., Lai, P., Esu, S., Massa, E., Ghiani, M., Dessì, D., Melis, G. B., et al. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970529)71:5<817::aid-ijc20>3.0.co;2-3 · Cited by 45
Doroshow, J. H., & Davies, K. J. A. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90399-4 · Cited by 45
Zhao, H. L., Traganos, F., & Darżynkiewicz, Z. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20574 · Cited by 45
DNA sequence specificity of mitoxantrone
Panousis, C., & Phillips, D. R. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.8.1342 · Cited by 40
Self-citationHuang, X., & Kurose, A. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.2878 · Cited by 40
Caffeine reverses the cytotoxic and cell kinetic effects of Novantrone (mitoxantrone)
Traganos, F., Kaminska‐Eddy, B., & Darżynkiewicz, Z. (1991) · Cell Proliferation · doi:10.1111/j.1365-2184.1991.tb01159.x · Cited by 40
Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?
Fulbright, J. M., Huh, W. W., Anderson, P. M., & Chandra, J. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0129-9 · Cited by 38
Liu, J., Liu, F., Tong, Z., Li, Z., Chen, W., Luo, W., Li, H., Luo, H., Tang, Y., Jun-min, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058957 · Cited by 36
Hasan, S. K., Ottone, T., Schlenk, R. F., Xiao, Y., Wiemels, J. L., Mitra, M. E., BERNASCONI, P. P., Raimondo, F. D., Stanghellini, M. T. L., Marco, P., et al. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20783 · Cited by 34
Low- to high-throughput analysis of telomerase modulators with Telospot
Cristofari, G., Reichenbach, P., Regamey, P., Banfi, D., Chambon, M., Turcatti, G., & Lingner, J. (2007) · Nature Methods · doi:10.1038/nmeth1099 · Cited by 33
Mitoxantrone Inhibits HIF-1α Expression in a Topoisomerase II–Independent Pathway
Toh, Y.-M., & Li, T.-K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0235 · Cited by 32
Wyhs, N., Walker, D., Giovinazzo, H., Yegnasubramanian, S., & Nelson, W. G. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114526433 · Cited by 32
Ambrosone, C. B., Barlow, W. E., Reynolds, W. F., Livingston, R. B., Yeh, I., Choi, J., Davis, W., Rae, J. M., Tang, L., Hutchins, L. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8669 · Cited by 32
Ferrer, A., Marcé, S., Bellosillo, B., Villamor, N., Bosch, F., López‐Guillermo, A., Espinet, B., Solé, F. G., Montserrat, E., Campo, E., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208084 · Cited by 30
Golubovskaya, V., Ho, B., Zheng, M., Magis, A. T., Ostrov, D. A., & Cance, W. G. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313040003 · Cited by 30
Catapano, C. V., Carbone, G. M., Pisani, F., Qiu, J., & Fernandes, D. (1997) · Biochemistry · doi:10.1021/bi963101b · Cited by 27
Consoli, U., Van, N., Neamati, N., Mahadevia, R., Beran, M., Zhao, S., & Andreeff, M. (1997) · Leukemia · doi:10.1038/sj.leu.2400511 · Cited by 27
Sado, K., Ayusawa, D., Enomoto, A., Suganuma, T., Oshimura, M., Sato, K., & Koyama, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010530200 · Cited by 27
Li, C., Zhao, X., Deng, C., Wang, C., Wei, N., & Cui, J. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.10.023 · Cited by 26
Formation of Topoisomerase IIα Complexes with Nascent DNA Is Related to VM-26-Induced Cytotoxicity
Qiu, J., Catapano, C. V., & Fernandes, D. (1996) · Biochemistry · doi:10.1021/bi9619637 · Cited by 25
The Effect of ATM and ERK1/2 Inhibition on Mitoxantrone-Induced Cell Death of Leukaemic Cells
Seifrtová, M., Havelek, R., Chmelařová, M., Ćmielová, J., Muthná, D., Stoklasova, A., Zemánková, S., & Řezáčová, M. (2011) · Folia Biologica · doi:10.14712/fb2011057020074 · Cited by 25
Cited by
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Guan, Y., Jiang, S., Ye, W., Ren, X., Wang, X., Zhang, Y., Yin, M., Wang, K., Tao, Y., Yang, J., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03153-x · Cited by 34
Metadata
- Authors
- Evison, B. J., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2015-08-19
- Volume
- 36
- Issue
- 2
- Pages
- 248-299
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W1929164375
- Cited by
- 253
- References
- 209
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.